secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001628280-24-013783
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo acquires AVTX-009 anti-IL-1β mAb, closes $115.6M private placement; 2023 net loss $31.5M
--------------------------------------------------------------------------------

- Acquired AVTX-009 (anti-IL-1β mAb) via acquisition of AlmataBio for $15M in stock plus $7.5M at close; milestones up to $20M.
- Closed private placement for up to $185M, initial $115.6M upfront; cash runway into 2027.
- 2023 net loss $31.5M ($114 per share); cash $7.4M at Dec 31, 2023.
- Plans Phase 2 trial in hidradenitis suppurativa; topline data expected in 2026.
- Warrants issued at $5.80 per share; as-converted shares ~23.4M after transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024013783/0001628280-24-013783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024013783/avtx-20240329.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-013783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer